ReviewDrug design, development and therapy2021

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.

Wajd Alkabbani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.